Resource Use in the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM): A Secondary Data Analysis.

ABSTRACT:

Background

Coronavirus disease 2019 (COVID-19) pneumonia requires considerable healthcare resources.

Research objective

Examine if a single dose of infliximab or abatacept, in addition to remdesivir and steroids, decreased resource utilization among participants hospitalized with COVID-19 pneumonia.

Study design and methods

Accelerating COVID-19 Therapeutic Interventions and Vaccines Immunomodulator (ACTIV-1 IM) master protocol was a randomized, placebo-controlled trial examining the potential benefit in time to recovery and mortality of immunomodulators infliximab, abatacept, and cenicriviroc. This observational study performs a secondary analysis of the infliximab, abatacept, and common placebo participants to examine resource utilization. Hospital days, intensive c

SUBMITTER: Lachiewicz AM 

PROVIDER: S-EPMC11600409 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature